Cargando…

Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma

IMPORTANCE: The association between treatment with first-line immuno-oncology (IO) combination therapies and physician-assessed objective imaging response among patients with metastatic renal cell carcinoma (mRCC) remains uncharacterized. OBJECTIVE: To compare the likelihood of objective imaging res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Navani, Vishal, Ernst, Matthew, Wells, J. Connor, Yuasa, Takeshi, Takemura, Kosuke, Donskov, Frede, Basappa, Naveen S., Schmidt, Andrew, Pal, Sumanta K., Meza, Luis, Wood, Lori A., Ernst, D. Scott, Szabados, Bernadett, Powles, Thomas, McKay, Rana R., Weickhardt, Andrew, Suarez, Cristina, Kapoor, Anil, Lee, Jae Lyun, Choueiri, Toni K., Heng, Daniel Y. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2022
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187954/ https://www.ncbi.nlm.nih.gov/pubmed/35687336 http://dx.doi.org/10.1001/jamanetworkopen.2022.16379

Ejemplares similares

Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
por: Gan, Chun Loo, et al.
Publicado: (2021)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Cytoreductive nephrectomy in the current treatment algorithm
por: Kuusk, Teele, et al.
Publicado: (2019)

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
por: Dudani, Shaan, et al.
Publicado: (2021)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

Characterizing the outcomes of metastatic papillary renal cell carcinoma
por: Connor Wells, John, et al.
Publicado: (2017)

Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors
por: Szabados, Bernadett, et al.
Publicado: (2020)

Contemporary Issues in Cancer Imaging: Lung Cancer
por: Navani, N, et al.
Publicado: (2008)

Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
por: Donskov, Frede
Publicado: (2021)

Prokhorov and Contemporary Probability Theory
por: Shiryaev, Albert, et al.
Publicado: (2013)

Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC)
por: Yip, Steven M., et al.
Publicado: (2017)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician
por: Storbjerg, Bent, et al.
Publicado: (2018)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Improving the inpatient oncology experience through a new consultant ward round
por: Navani, Vishal
Publicado: (2013)

Contemporary Correction of Dentofacial Anomalies: A Clinical Assessment
por: Adolphs, Nicolai, et al.
Publicado: (2016)

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.007
por: Allen-Tejerina, Andrea M., et al.
Publicado: (2021)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Oxaliplatin-Induced Neuropathy in Colorectal Cancer
por: Weickhardt, Andrew, et al.
Publicado: (2011)

Outcomes in Black and White Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors: Insights From Two Large Cohorts
por: Bossé, Dominick, et al.
Publicado: (2020)

Immuno-genomic landscape of osteosarcoma
por: Wu, Chia-Chin, et al.
Publicado: (2020)

Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
por: Schoenfeld, David A, et al.
Publicado: (2023)

Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy
por: Lau, David K., et al.
Publicado: (2019)

Contemporary sensorimotor theory
por: Bishop, John, et al.
Publicado: (2014)

The Bhagavad Gita and contemporary psychotherapies
por: Bhatia, Subhash C., et al.
Publicado: (2013)

Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer
por: Yekedüz, Emre, et al.
Publicado: (2023)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Hijacking Sexual Immuno-Privilege in GBM—An Immuno-Evasion Strategy
por: Sharpe, Martyn A., et al.
Publicado: (2021)

Elevated Levels of Asymmetric Dimethylarginine (ADMA) in the Pericardial Fluid of Cardiac Patients Correlate with Cardiac Hypertrophy
por: Nemeth, Zoltan, et al.
Publicado: (2015)

Targeting Progranulin as an Immuno-Neurology Therapeutic Approach
por: Boylan, Maria A., et al.
Publicado: (2023)

FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Impact of Geographic Regions on Overall Survival in Patients With Metastatic Renal Cell Carcinoma: Results From an International Clinical Trials Database
por: Fay, Andre P., et al.
Publicado: (2018)

How Advanced are Cancer Immuno-Nanotherapeutics? A Comprehensive Review of the Literature
por: Yadav, Dhananjay, et al.
Publicado: (2023)

Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis
por: Shen, Meixiao, et al.
Publicado: (2014)

Baseline blood volume identified by dynamic contrast-enhanced computed tomography as a new independent prognostic factor in metastatic renal cell carcinoma()
por: Drljevic-Nielsen, Aska, et al.
Publicado: (2020)

Blood Volume as a new functional image-based biomarker of progression in metastatic renal cell carcinoma
por: Drljevic-Nielsen, Aska, et al.
Publicado: (2021)

GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study
por: Juul, Simon, et al.
Publicado: (2022)

Immuno-Electrophoretic Analysis
por: Wood, Harrison F.
Publicado: (1965)

Cannot write session to /tmp/vufind_sessions/sess_siucab2sc77eo8lka6uk7ta1j4